
|Videos|January 31, 2019
First-Line Triplet in BRAF+ mCRC
Advertisement
An overview of the goals and design of the phase II single arm ANCHOR trial, which looks at the combination triplet regimen used in the BEACON study, encorafenib, binimetinib, and cetuximab, as first-line treatment for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5



































